Report cover image

NASH/MASH Treatment Market - 2025-2033

Publisher DataM Intelligence 4Market Research LLP
Published Mar 26, 2026
Length 210 Pages
SKU # DTAM21123665

Description

NASH/MASH Treatment Market Overview:
The NASH/MASH Treatment Market was valued at US$ 8.13 billion in 2025 and is anticipated to reach US$ 33.02 billion by 2033, at a CAGR of 0.1755 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the NASH/MASH Treatment Market.

This report delivers a comprehensive overview of the NASH/MASH Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding NASH/MASH Treatment Market. The NASH/MASH Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

NASH/MASH Treatment Market Scope:
By Drug
• Resmetirom (Rezdiffra)
• Lanifibranor
• Semaglutide
• Survodutide
• Pegozafermin
• Efruxifermin
• Denifanstat
• Others

By Stage
• Stage 0-1
• Stage 2-3
• Stage 4

By Age-Group
• Pediatrics
• Adults
• Geriatrics

By Gender
• Male
• Female

Key Players
• Madrigal Pharmaceuticals
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH.
• 89bio, Inc.
• Inventiva.
• CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
• Sagimet Biosciences.
• Akero Therapeutics, Inc. Similar data will be provided for each market player. LIST NOT EXHAUSTIVE

Major Highlights
This report delivers a comprehensive overview of the NASH/MASH Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding NASH/MASH Treatment Market. The NASH/MASH Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

210 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug
3.2. Snippet by Stage
3.3. Snippet by Age Group
3.4. Snippet by Gender
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of underlying conditions
4.1.1.2. Rising awareness on MASH
4.1.2. Restraints
4.1.2.1. Limited availability of approved drugs
4.1.2.2. Patient compliance issues
4.1.2.3. XX
4.1.3. Opportunities
4.1.3.1. Emerging drugs
4.1.3.2. Partnerships and collaborations
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis
6. By Drug
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
6.1.2. Market Attractiveness Index, By Drug
6.2. Resmetirom (Rezdiffra)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lanifibranor
6.4. Semaglutide
6.5. Survodutide
6.6. Pegozafermin
6.7. Efruxifermin
6.8. Denifanstat
6.9. Others
7. By Stage
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.1.2. Market Attractiveness Index, By Stage
7.2. Stage 0-1*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Stage 2-3
7.4. Stage 4
8. By Age-Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
8.1.2. Market Attractiveness Index, By Age-Group
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
8.4. Geriatrics
9. By Gender
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9.1.2. Market Attractiveness Index, By Gender
9.2. Male*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Female
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Madrigal Pharmaceuticals*
12.1.1. Company Overview
12.1.1.1. Product Portfolio
12.1.1.2. Product Description
12.1.1.3. Product Key Performance Indicators (KPIs)
12.1.1.4. Historic and Forecasted Product Sales
12.1.1.5. Product Sales Volume
12.1.2. Financial Overview
12.1.2.1. Company Revenue’s
12.1.2.2. Geographical Revenue Shares
12.1.2.3. Revenue Forecasts
12.1.3. Key Developments
12.1.3.1. Mergers & Acquisitions
12.1.3.2. Key Product Development Activities
12.1.3.3. Regulatory Approvals etc.
12.1.3.4. SWOT Analysis
12.2. Novo Nordisk A/S
12.3. Boehringer Ingelheim International GmbH.
12.4. 89bio, Inc.
12.5. Inventiva.
12.6. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
12.7. Sagimet Biosciences.
12.8. Akero Therapeutics, Inc. * Similar data will be provided for each market player. LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us